Antimicrobial Resistance (AMR)
AMR is an emerging and devastating global health problem caused directly by over-use of antibiotics. AMR jeopardizes our ability to perform many life-saving procedures such as major surgery and cancer therapy
  • In 2019, 1.3 million people died from antibiotic resistant infections, by 2050 as many as 10 million deaths are forecast if the situation is not changed.

    AdjuTec addresses this global problem by developing adjuvant technologies that inhibits key bacterial resistance mechanisms, restoring antibiotic efficacy against life-threatening, multidrug resistant bacterial infections.
  • Carbapenems e.g. meropenem, are antibiotics reserved for life-threatening infections. Carbapenemases are enzymes produced by bacteria that destroy carbapenems, conferring resistance to potentially deadly infections.

    AdjuTec develops products to inhibit the two main carbapenemase families, serine β-lactamases (SBL) and metallo-β-lactamases (MBL), also called β-lactamase-inhibitors (BLI).
Fungi cause diverse diseases in humans, ranging from allergic syndromes to superficial, disfiguring and life-threatening invasive fungal diseases, which together affect more than a billion people worldwide. Resistance to antifungal drugs is an emerging concern worldwide, including novel resistant variants of previously susceptible pathogens as well as entirely new emerging species that are resistant to multiple antifungal drugs. The increasing public health burden is now officially recognized with the listing of pathogens on the urgent AMR threat list published by the US CDC in 2019.
Adjutec supports academic research to develop novel antifungal products to meet this unmet medical need.
  • In 2020, approximately 700 000 people died from antibiotic resistant infections, by 2050 as many as 10 million deaths are forecast if the situation is not changed.

    AdjuTec addresses this global problem by developing adjuvant technologies that inhibits key bacterial resistance mechanisms, restoring antibiotic efficacy against life-threatening, multidrug resistant bacterial infections.
  • Carbapenems e.g. meropenem, are antibiotics reserved for life-threatening infections. Carbapenemases are enzymes produced by bacteria that destroy carbapenems, conferring resistance to potentially deadly infections.

    AdjuTec develops products to inhibit the two main carbapenemase families, serine β-lactamases (SBL) and metallo-β-lactamases (MBL), also called β-lactamase-inhibitors (BLI).
  • Fungi cause diverse diseases in humans, ranging from allergic syndromes to superficial, disfiguring and life-threatening invasive fungal diseases, which together affect more than a billion people worldwide. Resistance to antifungal drugs is an emerging concern worldwide, including novel resistant variants of previously susceptible pathogens as well as entirely new emerging species that are resistant to multiple antifungal drugs. The increasing public health burden is now officially recognized with the listing of pathogens on the urgent AMR threat list published by the US CDC in 2019.

    Adjutec supports academic research to develop novel antifungal products to meet this unmet medical need.
All products are covered by approved patents or patent applications.
APC277 is an academic project for treatment of resistant fungal infections.

APC148 is the AdjuTec lead BLI product that will be used as an adjuvant together with last-resort antibiotics. The target indication is patients with complicated Gram-negative infections. The product is in preclinical development, aiming at an IND/CTA application in 2023. The regulatory pathway has been discussed with FDA and EMA. FDA has granted APC148 a Qualified Infectious Disease Product designation, giving the product regulatory priority review and fast track review.

APC247 is a broad-spectrum BLI product that will be used as an adjuvant also together with last-resort antibiotics. The target indication is patients with complicated Gram-negative infections. The product is in early preclinical development.
Projects
Projects
APC148 is the AdjuTec lead BLI product that will be used as an adjuvant together with last-resort antibiotics. The target indication is patients with complicated Gram-negative infections. The product is in preclinical development, aiming at an IND/CTA application in 2023. The regulatory pathway has been discussed with FDA and EMA. FDA has granted APC148 a Qualified Infectious Disease Product designation, giving the product regulatory priority review and fast track review.

APC247 is a broad-spectrum BLI product that will be used as an adjuvant also together with last-resort antibiotics. The target indication is patients with complicated Gram-negative infections. The product is in early preclinical development.

APC277 is an academic project for treatment of resistant fungal infections.

All products are covered by approved patents or patent applications.
AdjuTec First-in-class Technology
metallo-β-lactamase resistance breaker APC148 destroys vital bacterial carbapenem-resistance mechanisms (MBL) and prevents the bacteria from defending itself from the antibiotic.